Chemical Regulation Without Insurance Puts Manufacturers at Risk

The Vermont Chamber testified in the House Judiciary Committee on S.113, a bill that proposes a cause of action for the remedy of medical monitoring for a person exposed to a proven toxic substance. The bill, as passed by the Senate, includes the Vermont Chamber’s recommendations from prior testimony in the Senate Judiciary Committee and an appropriate legal test for the remedy of awarding medical monitoring. The Vermont Chamber still has concerns regarding the insurance market and encouraged the Committee to hear from the Vermont Department of Financial Regulation on whether medical monitoring insurance can be written for Vermont companies. If not, several scenarios could disrupt the insurance markets, further impact our supply chains and economy, and subject manufacturers to significant risks and costs. To learn more, please contact Chris Carrigan